Evidence map›Paper›PMID 21082277›Full record

ArticleIn vitro cellular & developmental biology. Animal2011

Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background.

Saevar Ingthorsson, Thorhallur Halldorsson, Valgardur Sigurdsson, Agla J R Friðriksdottir, Sigridur K Bodvarsdottir, Margret Steinarsdottir, Oskar Johannsson, Magnus K Magnusson, Helga M Ogmundsdottir, Thorarinn Gudjonsson

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Saevar IngthorssonStem Cell Research Unit, Biomedical Center, University of Iceland and Department of Laboratory Hematology, Landspitali University Hospital, Reykjavik, Iceland.
Thorhallur Halldorsson
Valgardur Sigurdsson
Agla J R Friðriksdottir
Sigridur K Bodvarsdottir
Margret Steinarsdottir
Oskar Johannsson
Magnus K Magnusson
Helga M Ogmundsdottir
Thorarinn Gudjonsson
National University Hospital of Iceland · ISUniversity of Iceland · ISReykjavík University · ISUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An epithelial cell line, referred to as A163, was established from breast carcinoma derived from a patient with a strong family history of breast cancer but no known breast cancer susceptibility mutation. A163 was propagated in a serum-free culture medium including the epidermal growth factor. Immunophenotypic characterization demonstrated a mixed luminal and basal-like phenotype. When epidermal growth factor was excluded from the culture medium, A163 entered a quiescent period followed by a period of increased cell proliferation in a subpopulation of the cells. The epidermal growth factor-independent subpopulation retained the basal-like phenotype of the parental cell line. Karyotype and fluorescent in situ hybridization analysis showed an amplification of epidermal growth factor receptor on 7q in A163-S1 only, resulting in high expression of total and phosphorylated epidermal growth factor receptor. The A163-S1 sub-line piles up in culture, indicating a loss of contact inhibition. When grown on transwell filters, A163 shows basal expression of P63 and cytokeratin 14, whereas A163-S1 expresses P63 ubiquitously, and has lost the basal specific expression of cytokeratin 14, indicating a loss of polarity. Furthermore, when cultured in reconstituted basement membrane matrix, A163 form polarized normal like acini. In contrast, A163-S1 form large disorganized structures with lack of polarity. These cell lines may prove useful to understand molecular changes in breast cancer progression, in particular basal-like breast cancer subtype with bad prognosis and no current treatment options.

Indexed as

Cell Line, TumorGene AmplificationBreast NeoplasmsCarcinomaCell ProliferationCulture Media, Serum-FreeEpidermal Growth FactorEpithelial CellsErbB ReceptorsFemaleHumansMiddle AgedNeoplasms, Basal CellSelection, GeneticCulture Media, Serum-FreeEpidermal Growth FactorErbB Receptors

Identifiers

PMID21082277
OpenAlexW2039080023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.